The study of Griffiths et al. [41], though presenting a high risk of bias as to “attrition bias”(incomplete outcome data addressed; Supplementary Table 2), evidenced in patients withcomorbid Ps and depression the dose-dependent effects of a 12-week treatment withixekizumab, a high-affinity monoclonal antibody selectively targeting IL-17A. This evidence concerns the gene IL17A and depressive symptom measurement.